arrow
C

Curtis Cooper

university of ottawa
H指数:63
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis

Glecaprevir/Pibrentasvir在慢性HCV感染合并症或多种合并用药参与者中的疗效与安全性:一项综合分析

2026-04-080
OAAI
Ultrasensitive detection of HBsAg and HBV genome analysis in a prospective cohort with chronic hepatitis B after HBV surface antigen loss

慢性乙型肝炎患者队列在HBV表面抗原消失后,对HBsAg的超灵敏检测和HBV基因组的分析

2025-12-010
PRE
Immunogenicity and safety of third, fourth and subsequent COVID-19 vaccine doses in recipients of hematopoietic cell transplantation and cellular therapy

造血细胞移植和细胞治疗受者接种第三、第四及后续COVID-19疫苗剂量的免疫原性和安全性

2025-11-080
PRE
The 14th Canadian Symposium on Hepatitis C Virus: From research breakthroughs to equitable health care for priority populations

第14届加拿大丙型肝炎病毒研讨会: 从研究突破到优先人群的公平医疗保健

2025-11-010
PRE
Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies

多剂量SARS-CoV-2疫苗接种在血液恶性肿瘤患者中的增量免疫原性

2025-07-300
OAAI
COVID-19 vaccine uptake in a retrospective population-based cohort of people living with and without HIV in Ontario, Canada

加拿大安大略省HIV感染者与非感染者人群中COVID-19疫苗接种率的回顾性人群队列研究

Vaccine
IF3.5
2025-07-080
OA
Risk factors for infection with SARS-CoV-2 in a cohort of Canadian healthcare workers: 2020-2023

SARS-CoV-2感染的加拿大医疗保健工作者队列风险因素:2020-2023

2025-06-231
OAAI
Systemic and Mucosal Antibody Responses to SARS-CoV-2 Variant-Specific Prime-and-Boost and Prime-and-Spike Vaccination: A Comparison of Intramuscular and Intranasal Bivalent Vaccine Administration in a Murine Model

系统性及黏膜抗体对SARS-CoV-2变体特异性初始-加强和初始-刺突疫苗接种的应答:小鼠模型中肌肉注射与鼻内双价疫苗给药的比较

2025-03-250
OA
Coronavirus disease 2019 outcomes in a population-based cohort of people with HIV and a matched cohort of people without HIV during Omicron variant waves

在Omicron变体波期间,基于人群的HIV感染者队列和匹配的非HIV感染者队列的冠状病毒疾病2019结果

AIDS
IF3.1
2024-07-110
OAAI